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Abstract: Allergic asthma is associated with changes in neuronal
control in the airways that modulate inflammation and airway
hyperresponsiveness. The link between inflammation and neuronal
dysfunction is provided mainly by neurotrophins, in particular Brain
Derived Neurotrophic Factor (BDNF). In humans, significantly
higher serum BDNF levels have been observed in asthmatic patients
when compared with healthy subjects. BDNF levels are also signif-
icantly higher in untreated asthmatic patients in comparison to those
treated with inhaled glucocorticoids and nonasthmatic controls.
Allergic inflammation increases local BDNF production and its
concentration correlates with clinical parameters of allergic airway
dysfunction. The aim of this study was to analyze the possible
association of BDNF gene polymorphism with susceptibility to
asthma and disease severity. We analyzed 146 children diagnosed
with asthma and 227 children from the control group. Genotyping of
4 BDNF polymorphisms (rs12273363, rs7124442, rs6265, and
rs2030324) was done with use of PCR-RFLP and TaqMan SNP
genotyping assay. Genetic association analysis was performed in
Statistica. Linkage disequilibrium was determined with Haploview.
Single marker analysis revealed a significant association of C allele
of rs2030324 polymorphism with asthma susceptibility (P 0.048).
However, BDNF polymorphism was not associated with severe
asthma. Strong linkage disequilibrium was observed between all of
the BDNF polymorphisms analyzed grouped in one haplotype block.
We found a significant association of TTGC haplotype with asthma
(P  0.025). Our results suggest that genetic variation in the BDNF
gene may contribute to asthma susceptibility in case of rs2030324
polymorphism and TTGC haplotype, however it does not influence
asthma severity.
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INTRODUCTION
Asthma is the most common chronic disease of childhoodand is characterized by the reversible airflow obstruction
with chronic inflammation of the airways. Despite allergic
inflammation, dysregulation of lung neuronal network takes
place in asthma. Particularly important role in neuro-immu-
nologic interactions play neurotrophins that are able to reg-
ulate allergic inflammation. Brain-derived neurotrophic fac-
tor (BDNF) is one of key neurotrophins involved in the
regulation of differentiation and survival of various types of
neurons (including sensory neurons) and promotion of eosin-
ophils survival.
Increased BDNF levels have been found in bronchoal-
veolar lavage fluid after allergen challenge in allergic asth-
matic patients1,2 and BDNF levels are significantly higher in
untreated asthmatics in comparison to patients treated with
inhaled glucocorticoids and nonasthmatic controls.3 Further-
more, allergic inflammation increases local BDNF production
and enhanced BDNF concentration correlates with clinical
parameters of allergic airway dysfunction.4 The specificity of
BDNF to neuronal dysfunction in allergic inflammation is
supported by the finding that the reduction of serum BDNF
levels after inhaled glucocorticoid therapy is not correlated
with changes in acetylcholine responsiveness of the air-
ways.3 Recent report that dendritic cells may be activated
by neurotrophins such as BDNF or NGF suggests their role
in regulation of allergic sensitization and inflammation.5
However, neurotrophins may also act at levels different
from allergic inflammation, mediating in nonspecific air-
way responsiveness.
Given the biologic role of BDNF and conflicting results
from previous association studies, we assumed to investigate
further if the variation in the BDNF gene may be relevant for
asthma susceptibility and severity in Polish population.
SUBJECTS AND METHOD
Patients
The study was performed on Polish sample of 146
asthmatic patients of white origin in age from 6 to 18 years
old (86 boys with a mean age of 11.5 years, SD  3.5; 60
girls with a mean age of 11.7 years, SD  3.7). Patients were
recruited from inpatients from Wielkopolska region, consid-
ered as ethnically homogenous,6 and were treated for asthma
in the Department of Pediatric Pulmonology, Allergy and
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Clinical Immunology of Poznan University of Medical Sci-
ences. Asthma diagnosis was made according to GINA rec-
ommendation, based on clinical asthma symptoms and lung
function test (bronchodilator responsiveness, exercise in-
duced hyperresponsiveness); bronchodilator response was
assessed 20 minutes after administration of 200 mcg of
Salbutamol MDI via a holding chamber (Volumatic) and a
12% increase in FEV1 was diagnostic; bronchial hyperre-
sponsiveness was assessed by exercise test using a 6 minute
run on the treadmill and a postexercise fall in FEV1 of15%
was considered positive.
Severe asthma was defined as follows: symptoms re-
quiring daily therapy with high-dose inhaled corticosteroids
(800 mcg budesonide or 500 mcg fluticasone), despite
regular therapy with long acting 2-agonists and/or leukotri-
ene antagonist and/or theophylline (slow releasing), 1 or
more emergency care visit or oral steroids bursts per year. In
our group, 55 children met the criteria for severe asthma.
Clinical diagnosis of atopy depended on current or past
symptoms of atopic dermatitis, allergic rhinoconjunctivitis
(seasonal or perennial), or food allergy. Atopy was confirmed
in 105 children (72%) that fulfilled one of the after criteria:
total IgE level higher than the upper normal limits for age;
positive skin prick test to at least one aero-allergen (Dermato-
phagoides pteronyssinus, Dermatophagoides farinae, cat,
dog, feathers, Alternaria alternata, Cladosporium herbarum;
pollen: grass mix, rye, birch pollen, alder, hazel; Allergop-
harma, Germany). Any reaction with mean wheal diameter at
least 3 mm greater than negative control was regarded posi-
tive and defined atopy.7 Total serum IgE level was measured
by a fluoroimmunossay with Pharmacia UniCap 100 System
(Pharmacia, Uppsala, Sweden) following manufacturer’s in-
struction. The upper limits of normal range for total IgE was
age-dependent (70 kU/l for 6 years children; 79 KU/L for 7
years children, 89 KU/L for 8 years children, 98 KU/L for 9
years children, 107.0 KU/L for children of 10 years and
older).
Control Group
Control group consisted of 227 healthy subjects of
white origin (111 boys with a mean age of 11.5 years, SD 
3.0; 116 girls with a mean age of 12.4 years, SD  3.6).
Control subjects were also recruited from the same geo-
graphic region (Wielkopolska) from the group of carefully
chosen volunteers without asthma and allergy symptoms.
Any allergic diseases or asthma were excluded based on
clinical examination, history, spirometry, and exhaled NO
measurement.
All participants and their parents have given written
informed consent. Local ethics committee accepted the
project. Study was performed in compliance with the Code of
Ethics of the World Medical Association (Declaration of
Helsinki).
Genotyping
Four SNPs were chosen for analysis in this study;
rs6265 (Val66Met) that has been previously shown to alter
the intracellular trafficking and packaging of pro-BDNF8;
and 3 SNPs: rs2030324 (intronic) and rs12273363
(5UTR), and rs7124442 (3UTR) that were identified as
tag SNPs for the BDNF gene region utilizing HapMap
Caucasian data (www.hapmap.org/).
The DNA was extracted from 10 mL of EDTA antico-
agulated whole blood using the salting out method.9 Geno-
typing of 4 BDNF polymorphisms (rs12273363, rs7124442,
rs6265, and rs2030324) was done with use of PCR-RFLP and
TaqMan SNP genotyping assay C_27833027_10 (Applied
Biosystems). The sequences of the primers and conditions of
PCR-RFLP analysis for the 3 polymorphisms (rs12273363,
rs6265, and rs2030324) were shown in Table 1. The ampli-
fication for TaqMan SNP genotyping assay plates was done
in ABI PRISM 7900HT Sequence Detection System. Data
acquisition and analysis was performed using the allelic
discrimination analysis module in SDS v2.1 software (Ap-
plied Biosystems).
The uncut PCR products for BDNF polymorphisms
analyzed with PCR-RFLP (rs2030324 and rs6265) were di-
gested twice to confirm the results. For each reaction plate
genomic control DNA samples and nontemplate controls
(water) were included. The control of RFLP analysis and
TaqMan SNP genotyping assay was also performed (15% of
randomly chosen samples from both groups) to check for
genotyping accuracy. The genotyping was performed without
knowing the clinical outcome of the patient.
Statistical Analysis
The Pearson’s 2 test and Fisher exact test were used to
test differences in the genotypic and allelic, respectively,
distribution in case control. Calculations were performed
using the STATISTICA version 7.1 software. Odds ratios
(ORs) with a 95% confidence interval (CI) were calculated
using demo of GraphPad InStat 3 program. Concordance with










Rs12273363 5’-AGGCACAGCGATGCTGCAGAGGA-3’ 200 55 BseGI C: 34, 166 Own design
5’ CCTTGAAGCAGCCACTGAATG-3’ T: 34, 34, 132
Rs6265 5’-ACTCTGGAGAGCGTGAATGG-3’ 197 57 Eco72I A: 197 Own design
5’-AGAAGAGGAGGCTCCAAAGG-3’ G: 125 , 72
Rs2030324 5’ TTGCACATCCTGCTCAAGTC-3’ 348 55 TaiI T: 348 Own design
5’- TTGCTAGGAGAAAAGCCATGA C: 266, 82
Rs7124442 TaqMan genotyping assay C_27833027_10 — 60 — — Applied Biosystems
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Hardy-Weinberg law was performed using “Utility Programs
For Analysis Of Genetic Linkage” application (J. Ott,
1988). We also performed linkage disequilibrium analysis
of the analyzed polymorphisms of BDNF gene using free
online software Haploview version 4.1 from the Website
http://www.broad.mit.edu/mpg/haplview/index.php.10 Power
calculations were done in Quanto v.1.2.3 with OR values
between 1.0 and 1.4 and for two-sided associations were as
follows: for rs12273363 – 20%, for rs2030324 – 49%, for
rs6265 – 34.6%, and for rs7124442 – 42%.
RESULTS
Hardy-Weinberg Analysis
Genotype distributions for all studied polymorphisms
in the BDNF gene were in concordance with Hardy-Weinberg
law in both cases and control subjects (P  0.05).
Genotyping and Allele Frequencies
Minor allele frequencies for each BDNF polymorphism
were as follows: rs2030324 C  0.469; rs7124442 T 
0.248; rs12273363 T  0.149; and rs6265 G  0.177. The
genotyping success rates were between 94.5–98.6%. Geno-
typing error rates for all the polymorphisms were 1%.
Genetic Association Analysis
We found C allele of rs2030324 polymorphism to be
significantly associated with asthma (P  0.048). In analysis
stratified by sex this polymorphism was also associated with
asthma in boys (P  0.009) but not in girls (P  0.699). In
analysis of BDNF polymorphisms with asthma severity we
did not find any significant association (Table 2).
Linkage Disequilibrium and Haplotype Analysis
Moderate LD was observed between all of the BDNF
polymorphisms analyzed. Haploview analysis defined one
block for all the SNPs analyzed (Fig. 1). We observed 7
common haplotypes (estimated population frequency
0.005). Haplotype analysis for relationship with affection
status using Haploview found a significant association of
TTGC haplotype with asthma (Table 3). However, after
adjusting significance level for multiple comparisons using
10,000 permutations, we have found only marginal associa-
tion of this haplotype with asthma (P  0.07).
DISCUSSION
The main finding of our study is an association of
rs2030324 BDNF polymorphism with asthma in our pedi-
TABLE 2. Genotype Distributions and Allele Frequencies of
4 BDNF Polymorphisms for Asthmatic Patients Versus Control
Group (Figures in Parentheses Indicate Percentages)







CC 144 4 (2.78) 216 5 (2.31) 0.373 1.25 0.81–1.92
CT 30 (20.83) 59 (27.31)
TT 110 (76.39) 152 (70.37)
Alelles
C 288 38 (13.20) 432 69 (15.98) 0.336
T 250 (86.80) 363 (84.02)
Rs6265
Genotypes
AA 146 3 (2.05) 218 9 (4.13) 0.224
AG 37 (25.34) 68 (31.19) 1.42 0.95–2.12
GG 106 (72.60) 141 (64.68)
Alelles
A 292 43 (14.73) 436 86 (19.72) 0.092
G 249 (85.27) 350 (80.28)
Rs2030324
Genotypes
TT 146 31 (21.23) 214 53 (24.77) 0.061 1.35 1.00–1.82
CT 62 (42.47) 108 (50.47)
CC 53 (36.30) 53 (24.77)
Alelles
T 292 124 (42.50) 428 214 (50.00) 0.048*
C 168 (57.50) 214 (50.00)
Rs7124442
Genotypes
CC 131 79 (60.31) 227 126 (55.51) 0.354 0.93 0.68–1.32
CT 41 (31.30) 87 (38.33)
TT 11 (8.40) 14 (6.17)
Alelles
C 262 199 (75.96) 454 339 (74.67) 0.720
T 63 (24.04) 115 (25.33)
*Indicates significance.
FIGURE 1. Relative positions and LD estimates between 4
BDNF polymorphisms in the analyzed population. Coloured
squares correspond to D’ values with numerical estimates
given within the squares.
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atric population. This association was also observed for the
male sex. No association was found for the other studied
polymorphisms.
Previous studies investigating the impact of genetic
variation in BDNF have shown conflicting results.7,11,12 Neg-
ative association results presented here for 3 BDNF polymor-
phisms (rs12273363, rs7124442, rs6265) are consistent with
those obtained in a German cohort11 and also with data
published for a large British cohort of asthmatic siblings.12
However, the association observed for rs2030324 polymor-
phism was not observed previously.12 It is difficult to discuss
our results as there are no other studies available for asthma
that could verify our results. The recent study by Zeilinger et
al11 reported no association of BDNF gene with asthma or
any atopic disease in a large pediatric ISAAC cohort. How-
ever, the associated rs2030324 polymorphism was not among
those SNPs analyzed by this group.
In linkage disequilibrium analysis we observed moder-
ate linkage between 4 analyzed BDNF polymorphisms lo-
cated in one LD block. In this block we found that TTGC
haplotype was associated with higher risk of developing
asthma in our population. Such an association was not found
previously.12 This may result not only from the differences in
sample size, but also from ethnic disparities between the
Polish and British samples.
The main limitation of our study is a relatively small
sample size in comparison to the other studies reporting on
the role of BDNF polymorphism in asthma. However, our
group of patients and controls is carefully characterized with
doctor’s diagnosis (or asthma exclusion in controls) con-
firmed by lung function tests and clinical markers of allergic
inflammation (skin, prick test, elevated IgE level, comorbid
atopic diseases).
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TABLE 3. Results of Haploview Haplotype Analysis







TTGC 0.494 0.545, 0.461 5.013 0.025*
TTAT 0.165 0.140, 0.182 2.362 0.124
CCGT 0.124 0.118, 0.129 0.182 0.670
TCGT 0.099 0.097, 0.101 0.035 0.852
TTGT 0.067 0.057, 0.074 0.793 0.373
TCGC 0.018 0.024, 0.013 1.184 0.276
CTGT 0.011 0.012, 0.011 0.023 0.878
*Indicates significance.
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